A few more key differentiators: Wegovy is available as a weekly subcutaneous (under-the-skin) injection and a daily oral tablet
Given that there are no major, obvious differences in tolerability, efficacy on glycemic parameters, weight loss, or overt advantages regarding administration, it is likely that the use of LIXI in place of other GLP-1 agonists will be based on cost (79)
Costs for subcutaneous liraglutide, subcutaneous semaglutide, and subcutaneous tirzepatide varied by 30% of their base-case values to reflect discounts typically applied by wholesalers in the drug supply chain
All doses 10 mg can be drawn from one reconstituted 10 mg vial with 1.0 mL reconstitution
B.et al (2000)
Personalized GLP-1 Selection Using Genetic Insights Rather than guessing which GLP-1 agent will work best, PlexusDx uses the Precision Peptide Genetic Test ($298) to analyze your genetic predispositions across 49 peptides and 14 metabolic pathways